News and Trends 15 Mar 2018 This Swedish Discovery Could Change the Way We Treat Diabetes Swedish researchers have found that insulin-producing cells alone are not enough to fine-tune blood sugar levels. This could change the way diabetes treatments are designed. While it is known that certain clusters of cells in the pancreas called pancreatic islets influence the set point for blood sugar, the exact mechanisms are still unknown. The control of […] March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Takes its Oral Diabetes Drug to Phase III Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […] March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2018 French Biotech Targets Gut Microbiome to Treat Diabetes Valbiotis has shown that its treatment restores diversity in a population of gut microorganisms imbalanced by type 2 diabetes in mice. Valbiotis, based in Périgny, France, wants to treat type 2 diabetes by restoring the balance of microbial populations in the gut microbiome. New data from a metagenomic sequencing study in mice has shown that its drug, […] March 8, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2018 Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […] February 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2018 This Mobile Diabetes Management System Can Reduce Hypoglycemia by 39% The wireless system for diabetes management developed by Cellnovo can significantly reduce life-threatening events of hypoglycemia in patients with type 1 diabetes. A clinical study that followed type 1 diabetes patients for a year has concluded that a new mobile system for diabetes management could reduce events of hypoglycemia by 29% in adults — from […] February 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2018 Watch Out Eli Lilly: Novo’s Diabetes Drug Ozempic Gets European Approval Update (13/02/2018): The European Commission has given Novo Nordisk a market authorization for Ozempic (semaglutide), bringing the competition for Eli Lilly’s Trulicity over to Europe. Eli Lilly executives have said that they are not worried by Novo’s competition, and keep confident on the performance of Trulicity, which now tops 40% of the market share of diabetes drugs belonging […] February 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes. Poxel uses its expertise in metabolism to develop drugs for the treatment of disorders like type 2 diabetes. Its candidate imeglimin has caught the eye of […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 25 Jan 2018 What Happened to the Plans for a Smart Contact Lens for Diabetics? Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but a recent study predicts that the market will pick up this year introducing innovative products to the consumer market: according to CCS Insight, the market for […] January 25, 2018 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 This is Why You Should Avoid Eating too Much Junk Food Following last week’s article about the importance of eating plenty of fruit and vegetables, German researchers have unearthed another link between junk food and diabetes and heart disease. Researchers from the University of Bonn, Germany, have found that an unhealthy diet can cause the immune system to act as if it is responding to bacterial […] January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2017 An FDA First! Sanofi’s “Follow-on” Insulin Gets a Thumbs Up Sanofi’s rapid-action insulin, Admelog, will be the first “follow-on” insulin product on the market to help diabetics manage their blood sugar at mealtimes. Sanofi has announced the FDA approval of Admelog, the first “follow-on” mealtime insulin available to type 1 and type 2 diabetics. This gave the company’s stock price a boost of 1.1% this morning, which is […] December 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes in new formulations of therapeutic proteins, particularly for the treatment of diabetes. Just last week, Adocia’s glucagon treatment for hypoglycemia was proved to be safe in a Phase I study. Today, the biotech has announced that its […] December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 The Link Between Type 2 Diabetes and Obesity may have Finally been Uncovered Researchers at the Université de Genève have unravelled the cellular and molecular mechanisms linking obesity and insulin resistance. We have long known about a link between obesity and type 2 diabetes, but discovering the underlying mechanisms has proved difficult. A group of researchers at the Université de Genève, Switzerland, may have found a protein that links changes […] November 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email